StockData
NervGen Pharma Corp. logo

NervGen Pharma Corp. (NGEN) company profile

NGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$1.96+0.14 (+7.69%)

Close on Nov 17, 2026Market cap $156.11MP/E –Yield –

About NervGen Pharma

Pharmaceutical Preparations, SIC 2834

NervGen Pharma Corp. is a pharmaceutical company based in Canada that engages in scientific research and experimental development. The company focuses its operational efforts on preclinical development, clinical and regulatory activities, chemistry manufacturing and controls, and the licensing and protection of patents. Operating as a development-stage enterprise within the pharmaceutical preparations industry, the business does not report distinct commercial operating segments or commercial product sales to external customers. Its core activities center on proprietary research, development initiatives, and related advisory work directed by executive leadership and medical advisors.

The company maintains its corporate headquarters and principal executive offices in Vancouver, British Columbia, Canada. Its administrative and corporate operations encompass organizational relationships, regulatory reporting, and legal processes spanning Canada, the United States, and Australia. The company manages executive functions, board committees, and compliance procedures from its Canadian base. No retail stores, manufacturing facilities, or physical branch networks are reported in the filing.

Summary of the business section of NervGen Pharma's latest annual report, written by StockData.

Company profile

Company

Legal name
NervGen Pharma Corp.
Headquarters
Vancouver, British Columbia, Canada
Address
112-970 Burrard Street, Suite 1290 V6Z 2R4
Phone
(778) 731-1711
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
KPMG LLP, Vancouver, Canada

Stock & identifiers

Ticker
NGEN
Exchange
Nasdaq
IPO date
Apr 3, 2019
Shares outstanding
80M, Dec 31, 2025
Filer category
<br>Emerging growth company
SEC CIK
1751912
CUSIP
64082X203
ISIN
US64082X2036
FIGI
BBG00NQ5C032
Share class FIGI
BBG00MMMWGD3
EIN
98-1738183

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

NervGen Pharma's leadership is listed in its proxy statement (Form DEF 14A).

Corporate history

Events identified from SEC filings

See a number that looks wrong?